Cobitolimod

Summary

Cobitolimod (CHEMBL4297564) is a phase-3 clinical-stage oligonucleotide; indicated across 1 condition including ulcerative colitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297564
Name	Cobitolimod
Type	Oligonucleotide
Max phase	3

Also known as: Cobitolimod, COBITOLIMOD

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ulcerative colitis	3	MONDO:0005101	EFO:0000729

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01493960	PHASE3	COMPLETED	The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
NCT04985968	PHASE3	TERMINATED	The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT03178669	PHASE2	COMPLETED	The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
NCT05404074	PHASE1	UNKNOWN	Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).